Cloudbreak Therapeutics, a Chinese clinical-stage biotechnology company focusing on ocular drug development, has recently completed a Series B round of fundraising at RMB180 million (US$25.4 million), led by Chinese venture capital firm V-Capital. GrandPharma, BOC International and Lumiere Fund poured money into the new round. The funds will be mainly used to promote the clinical […] V-Capital Leads $25M New Round In Ocular Drug Developer Cloudbreak Therapeutics comes from China Money Network: Primary Data for China's Primary Markets! All Rights Reserved.